Table 1.
Studies included in the meta-analysis
| Study author, year |
Checked with author |
Research group |
Subject groups |
N | MMSE/30 at baseline mean (S.D.) <number of subjects> |
Age, years at first MRI mean (S.D.) |
Annualised loss of total volume (left plus right hippocampi) mean % year−1 (S.D.) |
Interval (years unless specified) mean (S.D.) |
|---|---|---|---|---|---|---|---|---|
| Barnes et al. (2007b) | Yes | Fox et al. | C | 19 | 29.5 (0.7) | 68.7 (7.0) | 0.32 (0.93) | 365 (5) days |
| AD | 36 | 19.4 (4.1) | 69.6 (7.3) | 4.52 (2.94) | 365 (18) days | |||
| Du et al. (2004) | Yes | Weiner et al. | C | 25 | 29.0 (1.0) | 76.8 (7.8) | 0.8 (1.7) | 2.0 (0.7) |
| AD | 20 | 21.0 (7.2) | 75.3 (7.2) | 5.9 (2.4) | 1.8 (0.7) | |||
| Fox et al. (2005) | Yes | Fox et al. | AD -placebo | 57 | 20.2 (3.5) | 70.7 (8.2) | 3.16 (3.51) | 10.9 (1.1) months |
| Hashimoto et al. (2005) | Yes | Hashimoto et al. | AD no treat | 93 | 21.6 (2.8) | 70.5 (9.1) | 5.04 (2.54) | 392 (35) days |
| AD treat | 54 | 21.8 (3.9) | 69.5 (9.5) | 3.82 (2.84) | 388 (29) days | |||
| Jack et al. (2004) | Yes | Jack et al. | C stab | 40 | 29.0 (0.9) <34> | 78.2 (7.7) | 1.4 (0.7) | 4.3 (0.7) |
| AD slow | 31 | 22.3 (4.4) <30> | 73.9 (6.9) | 3.9 (2.6) | 1.4 (0.4) | |||
| AD Fast | 33 | 19.5 (4.0) <32> | 77.8 (8.4) | 4.8 (3.2) | 1.4 (0.4) | |||
| Jack et al. (2003) | Means and S.D.s given by personal communication |
Jack et al. | AD | 192 | 20.8 (4.1) | 72.8 (7.7) | 5.5 (3.3) | 1.0 (0.1) |
| Kaye et al. (2005) | Yes | Kaye et al. | C | 88 | 28.3 (1.5) | 83.0 (7.0) | 2.2 (6.0) | 2.04 (1.42) |
| AD mild | 27 | 21.7 (4.5) | 76.1 (7.1) | 2.9 (7.8) | ||||
| AD moderate | 17 | 16.8 (6.7) | 75.1 (6.2) | 3.2 (6.8) | ||||
| Thompson et al. (2004) | Erratum in Neuroimage 2007 36,1397–8. Values here are correct |
Thompson et al. | C | 14 | 29.5 (0.9) | 71.4 (3.2) | 2.1 (2.8) | 2.6 (1.0) |
| AD | 17 | 16.8 (6.6) | 68.7 (6.8) | 6.8 (10.2) | 1.3 (0.9) | |||
| Wang et al. (2003) | Yes | Csernansky et al. | C | 26 | 29.0 (1.3) <13> | 73 (7.0) | 2.3 (1.9) | 2.2 (0.53) |
| DAT | 18 | 25.7 (3.9) <12> | 74 (4.4) | 5.1 (2.8) | 2.0 (0.37) |
Key: AD, Alzheimer’s disease; C, control; DAT, dementia of Alzheimer type; <> number of subjects on which information has been obtained; italicized: information from personal communication; C stab, stable controls; AD fast, fast progressing AD; AD slow, slow progressing AD; AD mild, mildly affected AD subjects; AD moderate, moderately affected AD subjects; AD placebo, AD subjects on placebo; AD treat, treated AD (symptomatic treatment); AD non-treat, AD not treated with symptomatic treatment.